Murovic Judith A, Kim Daniel H, Kline David G
Department of Neurosurgery, Stanford University Medical Center, Stanford, California 94305-5327, USA.
Neurosurg Focus. 2006 Jan 15;20(1):E1. doi: 10.3171/foc.2006.20.1.2.
In this paper the authors describe a patient with neurofibromatosis Type 1 (NF1) who presented with sequelae of this disease. They also review the current literature on NF1 and NF2 published between 2001 and 2005. The method used to obtain information for the case report consisted of a family member interview and a review of the patient's chart. For the literature review the authors used the search engine Ovid Medline to identify papers published on the topic between 2001 and 2005. Neurofibromatosis Type 1 appears in approximately one in 2500 to 4000 births, is caused by a defect on 17q11.2, and results in neurofibromin inactivation. The authors reviewed the current literature with regard to the following aspects of this disease: 1) diagnostic criteria for NF1; 2) criteria for other NF1-associated manifestations; 3) malignant peripheral nerve sheath tumors (PNSTs); 4) the examination protocol for a patient with an NF1-related NST; 5) imaging findings in patients with NF1; 6) other diagnostic studies; 7) surgical and adjuvant treatment for NSTs and malignant PNSTs; and 8) hormone receptors in NF1-related tumors. Pertinent illustrations are included. Neurofibromatosis Type 2 occurs much less frequently than NF1, that is, in one in 33,000 births. Mutations in NF2 occur on 22q12 and result in inactivation of the tumor suppressor merlin. The following data on this disease are presented: 1) diagnostic criteria for NF2; 2) criteria for other NF2 manifestations; 3) malignant PNSTs in patients with NF2; 4) examination protocol for the patient with NF2 who has an NST; and 5) imaging findings in patients with NF2. Relevant illustrations are included. It is important that neurosurgeons be aware of the sequelae of NF1 and NF2, because they may be called on to treat these conditions.
在本文中,作者描述了一名患有1型神经纤维瘤病(NF1)的患者及其疾病后遗症。他们还回顾了2001年至2005年间发表的关于NF1和NF2的当前文献。用于获取病例报告信息的方法包括对家庭成员进行访谈以及查阅患者病历。对于文献综述,作者使用搜索引擎Ovid Medline来识别2001年至2005年间发表的关于该主题的论文。1型神经纤维瘤病在大约每2500至4000例出生中出现1例,由17q11.2上的缺陷引起,导致神经纤维瘤蛋白失活。作者从以下几个方面回顾了关于这种疾病的当前文献:1)NF1的诊断标准;2)其他与NF1相关表现的标准;3)恶性外周神经鞘瘤(PNSTs);4)患有与NF1相关的神经鞘瘤(NST)患者的检查方案;5)NF1患者的影像学表现;6)其他诊断研究;7)NST和恶性PNST的手术及辅助治疗;8)NF1相关肿瘤中的激素受体。文中包含了相关插图。2型神经纤维瘤病(NF2)的发病率比NF1低得多,即每33000例出生中出现1例。NF2的突变发生在22q12,导致肿瘤抑制因子默林失活。文中给出了关于这种疾病的以下数据:1)NF2的诊断标准;2)其他NF2表现的标准;3)NF2患者中的恶性PNSTs;4)患有NST的NF2患者的检查方案;5)NF2患者的影像学表现。文中包含了相关插图。神经外科医生了解NF1和NF2的后遗症很重要,因为他们可能会被要求治疗这些病症。